Set Cookies

Medtronic maakt op deze website gebruik van Google Analytics, een webanalysedienst die uw gebruik van de website analyseert door middel van het gebruik van cookies. Uw IP-adres wordt door Google geanonimiseerd waardoor tracking op individueel niveau technisch onmogelijk is.

Voor meer informatie verwijzen wij u naar ons Cookiebeleid.

Hieronder kunt u aangeven of u voornoemde cookies toestaat.

Cookies niet toestaan Cookies toestaan

Click here for English.

Medtronic uses Google Analytics, a web analysis service that uses cookies to analyze your use of this website. Google depersonalises your IP address, making tracking at an individual level technically impossible.

For further information, please refer to our cookie policy.

Below you can indicate whether you accept the aforementioned cookies.

Reject cookies Allow cookies

Klik hier voor Nederlands.


Diabetes is the fifth largest Medtronic business unit. For more than 30 years, we've been helping people with diabetes manage their glucose levels and live longer, healthier lives. We offer an integrated diabetes management system, including an insulin pump, continuous glucose monitoring (CGM), insulin delivery and therapy management tools. Studies demonstrate that this integrated system can provide better glucose control1,2 compared to multiple daily injections (MDI), so the risk of long-term complications3 and the impact of hypoglycaemia4,5 can be reduced. It also extends our lead on the path to developing an artificial pancreas ‒ a “closed-loop” insulin delivery system.

Key Product Categories

Insulin Pumps*

Medtronic insulin pump

Insulin pumps are devices that deliver precise doses of rapid-acting insulin to closely match the body’s needs. They are small in size — about the size of a mobile phone — and worn externally (not implanted), and can be discreetly clipped to a belt, slipped into a pocket, and hidden under clothing. It gives people with diabetes the freedom they want without worrying about injections and special food.Today, we have the only insulin pump integrated with a continuous glucose monitoring feature which can help reduce the impact of hypoglycaemia3,4.


Continuous Glucose Monitoring Systems*


With Continuous Glucose Monitoring (CGM), people with diabetes get a more complete picture of their glucose levels, which can lead to better treatment decisions and better glucose control1,2. CGM measures glucose levels in real time 24 hours a day. CGM provides the direction glucose levels are going; early notification of oncoming lows and highs; alerts for lows or highs while the patient is sleeping; and insights into how food, physical activity, medication, and illness impact glucose levels.

A CGM system consists of:

  • A glucose sensor inserted under the skin that measures glucose levels.
  • A transmitter that sends the glucose information from the sensor to the insulin pump through advanced radio frequency (RF) wireless technology.
  • An insulin pump that displays glucose levels on the pump’s screen and notifies the user if it detects that glucose is reaching a high or low limit.


Insulin delivery

Medtronic infusion sets and reservoirs

Selecting a safe and reliable infusion set and reservoir to suit the lifestyle of people with diabetes is important for successful pump therapy. Our infusion sets and reservoirs* are thoroughly tested to ensure a consistent insulin delivery. Their unique design enables changing the set as quick and convenient as possible.


Therapy Management Tools*

Medtronic CareLink Therapy Management Tools for Diabetes

Our online diabetes therapy management software brings together critical information from a patient's insulin pump, continuous glucose monitor, and blood glucose meter. It turns the information into reports, which help to understand the effects of insulin, carbohydrates and exercise on glucose levels. It also allows the healthcare professional to see their patient’s data from their hospital computer.


More information
See our


  1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
  2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311-20.
  3. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med 2009;169:1307-16.
  4. Garg S et al. Automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther 2012;14:205–209.
  5. Danne T, et al. Prevention of Hypoglycemia by Using Low Glucose Suspend Function in Sensor-Augmented Pump Therapy. Diabet Technol Therapeut 2011;13:1–6.


*For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use.

Section Navigation

Additional information


Medtronic was ranked number 16 in the list of Best Workplaces in the Netherlands in 2017!

Best Employer 2017

For more information